Eli Lilly Shares Plunge as Bernie Sanders Criticizes Humalog Price Hikes

Share This Article
November 1, 2016 2:59pm NYSE:LLY

biotech-white-pillsShares of Eli Lilly and Co (NYSE:LLY) plunged to seven-month lows this afternoon, following a scathing tweet from Bernie Sanders that criticized the price of the drug giant’s insulin product, Humalog.


LLY, which was already reeling on the day, quickly sank when Sanders published this tweet:

Humalog is one of Lilly’s flagship drugs, generating sales of $641 million in the second quarter alone. According to PMLive.com, Humalog was the 35th highest grossing drug in the world in 2014.

Much of that revenue is due to massive price increases. As Sanders points out, Humalog’s inflation-adjusted price has grown from $21 per vial in 1996 to $255 per vial this year. That’s an 1100% price increase in twenty years, during which Lilly has boosted the price over two dozen times.

Today marks the second time in the past few weeks that Sanders has publicly pointed shamed drug industry pricing. Last month, his tweet targeting high-flying Ariad Pharmaceuticals caused the company’s stock to plummet 14% in a matter of minutes. We warned investors back then to expect more criticism and intervention from politicians, and more share price crashes as a result.

Eli Lilly shares fell $1.13 (-1.53%) to $72.71 in Tuesday afternoon trading. Year-to-date, LLY has plunged 13.65%, versus a 3.27% gain in the benchmark S&P 500 during the same period.

LLY-2016-11-01


9 "Must Own" Growth Stocks For 2019

Read Next



Get Free Updates

Join over 50,000 investors who get the latest news from ETFDailyNews.com!

Most Popular



Explore More from ETFDailyNews.com

Free Daily Newsletter

Get daily ETF insights from our market experts. Never miss another important market development again!

ETFDailyNews.com respects your privacy.

Best ETFs

We've rated and ranked nearly 2,000 ETFs and ETNs using our proprietary SMART Grade system.

View Top Rated ETFs

Best Categories

We've ranked dozens of ETF categories based on relative performance.

Best ETF Categories